The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease
Open accessAbstract
Glial cell line-derived neurotrophic factor (GDNF) has shown promise in the treatment of neurodegenerative disorders of basal ganglia origin such us Parkinson's disease (PD). In this study, we investigated the neurorestorative effect of controlled GDNF delivery using biodegradable microspheres in an animal model with partial dopaminergic lesion. Microspheres were loaded with N-glycosylated recombinant GDNF and prepared using the Total Recirculation One-Machine System (TROMS). GDNF-loaded microparticles were unilaterally injected into the rat striatum by stereotaxic surgery two weeks after a unilateral partial 6-OHDA nigrostriatal lesion. Animals were tested for amphetamine-induced rotational asymmetry at different times and were sacrificed two months after microsphere implantation for immunohistochemical analysis. The putative presence of serum IgG antibodies against rat glycosylated GDNF was analyzed for addressing safety issues. The results demonstrated that GDNF-loaded microspheres, improved the rotational behavior induced by amphetamine of the GDNF-treated animals together with an increase in the density of TH positive fibers at the striatal level. The developed GDNF-loaded microparticles proved to be suitable to release biologically active GDNF over up to 5 weeks in vivo. Furthermore, none of the animals developed antibodies against GDNF demonstrating the safety of glycosylated GDNF use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apart from this GDNF-loaded microsphere increase in TH-positive fibers in the striatum and substantia nigra, the results suggested neuroprotection and neurorestoration activity.129,130”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [130]
In the citing paper
“Similar results were also observed by Garbayo et al., where PLGA-MS-mediated GDNF release demonstrated antiparkinsonian effects, as confirmed by the improvement in the amphetamine-induced rotational behavior test.130”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [130]
Citations
Cites
The rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J. L., Chen, E., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251
Lang, A. E., Gill, S., Patel, N., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G. R., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 987
Kirik, D., Rosenblad, C., & Björklund, A. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6848 · Cited by 663
Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R. J., & Young, B. A. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 474
Patel, N. K., Bunnage, M., Plaha, P., Svendsen, C. N., Heywood, P. G., & Gill, S. S. (2005) · Annals of Neurology · doi:10.1002/ana.20374 · Cited by 384
Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility
Fournier, E., Passirani, C., Montero‐Menei, C. N., & Benoît, J. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00161-3 · Cited by 353
Self-citation
Cited by
Sorted by citations
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Breton, A. L., & Véronique Préat, A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 4,006
Self-citationGDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Current and Novel Polymeric Biomaterials for Neural Tissue Engineering
Boni, R., Ali, A., Shavandi, A., & Clarkson, A. N. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0491-8 · Cited by 439
Biomaterials for promoting brain protection, repair and regeneration
Orive, G., Anitua, E., Pedraz, J. L., & Emerich, D. F. (2009) · Nature reviews. Neuroscience · doi:10.1038/nrn2685 · Cited by 421
Metadata
- Authors
- Garbayo, E., Montero-Menei, C. N., Ansorena, E., Lanciego, J. L., Aymerich, M. S., & Blanco-Prieto, M. J.
- Affiliations
- Universidad de Navarra (ES)
- Centro de Investigación Médica Aplicada (ES)
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 135
- Issue
- 2
- Pages
- 119-126
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2075997145
- Cited by
- 150
- References
- 29
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 13 · 2019: 5 · 2018: 9 · 2017: 9 · 2016: 15 · 2015: 18 · 2014: 10 · 2013: 14 · 2012: 13
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- glial cell line-derived neurotrophic factor, Parkinson's disease, biodegradable microspheres, controlled drug delivery, 6-hydroxydopamine lesion, nigrostriatal degeneration, striatum, amphetamine-induced rotation, tyrosine hydroxylase, neurorestoration, immunogenicity
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Brain, Cell Differentiation, Corpus Striatum, Disease Models, Animal, Drug Carriers, Female, Glycosylation, Immunohistochemistry, Kinetics, Microspheres, Models, Neurological, Parkinson Disease, Particle Size, Polyglycolic Acid, Recombinant Proteins, Drug Delivery Systems, PC12 Cells, Rats, Sprague-Dawley, Fluorescent Antibody Technique, Indirect, Lactic Acid, Glial Cell Line-Derived Neurotrophic Factor, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
